Calendario›SNY›Dupilumab · DEDICATION
Dupilumab · DEDICATION
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Ensayo de Sanofi en Urticaria cronica espontanea.
Más ensayos de: Urticaria crónica espontánea.
- Fase
- no aplica
- Estado
- Interrumpido
- Participantes
- 1
- Centros
- 1
- Fin del objetivo primario
- jun 2026
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en mar 2026.
Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Sponsor decision; the decision is not related to any safety concern.».
Qué mide
Summary of Sociodemographic Characteristics (del registro, en inglés) (inicio)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a decentralized study designed to describe the real-world effectiveness, safety, and patterns of use of dupilumab in patients with chronic spontaneous urticaria (CSU). This study will be conducted in the United States and will collect data available from participants' medical files, other items routinely collected during disease management in clinical practice, and patient-reported outcomes related to disease, work productivity, quality of life, and CSU-related hospitalizations. Participation in this study is the patient's own choice and is entirely voluntary. The treating physician prescribes dupilumab treatment as part of routine care, independently of the study. Once the decision to prescribe dupilumab is made by the treating physician, patients can self-screen and will be contacted by the Virtual Research Coordination Center to determine potential study eligibility. Patients will be enrolled if they provide an informed consent and meet all inclusion criteria and none of the exclusion criteria. The duration of the study for each participant is 24 months. All patients will be followed for 24 months or until death, loss to follow-up, or withdrawal, whichever occurs first.
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07316114), actualizada en jul 2026.